Enesi Pharma, a UK-based pharmaceutical firm focused on manufacturing novel injectable solid-dose vaccines, has reportedly announced to have formed a research and development collaboration with Public Health England (PHE).
As per trusted sources, the partnership would focus on developing and evaluating unique solid-dose formulations of a number of proprietary vaccine products of PHE including Crimean-Congo Haemorrhagic Fever (CCHF) and Anthrax recombinant Protective Antigen (rPA) for delivery through ImplaVax® needle-free technology of Enesi Pharma.
Reportedly, pre-clinical testing of a number of ImplaVax-enabled vaccines in animals has shown a reduced time to achieve threshold immunity and regimen sparing against the conventional liquid vaccines dispensed via a syringe and needle. Apart from saving money and time, such regimen sparing enables vaccination of more patients more swiftly with potentially expanding coverage, fixed available production volume, and in emergency response situations.
Chief Executive Officer of Enesi Pharma, David Hipkiss, was reportedly quoted stating that the company has been encouraged with the affirmative response received from institutions to the potential advantages of the ImplaVax solid-dose vaccine platform.
According to trusted sources, ImplaVax-enabled vaccines benefit from added thermal stability which greatly assists in optimizing the cost-effectiveness of the national strategic stockpile and reduces capital costs along with the end to end cold chain logistical challenges.
Moreover, the vaccination schedules of numerous vaccines in the present times need multiple doses. Therefore, an ImplaVax-enabled vaccine has the potential to dramatically improve the vaccination programs for the military and other at-risk personnel, cite trusted sources. These vaccines also provide a swiftly-deployable therapeutic option for people who have been exposed to infectious diseases.
For the record, PHE is an executive agency of the Department of Health and Social Care of the Government of United Kingdom. Head of Research and Deputy Director at PHE, Prof Miles Carroll, was reportedly quoted commenting that the threat of emerging infections is an important public health consideration and the ImplaVax technology of Enesi could improve the vaccination process.
